Eagle Genomics is a biotechnology startup based in United Kingdom that focuses on networking microbiome science. Founded in 2008, the company's mission is to reveal the impact of the microbiome on humans, animals, and the environment to ensure a sustainable future for food, water, soil, and overall planetary health. Eagle Genomics aims to deliver insights from the microbiome to fundamentally change our understanding of wellness and life on earth.
The company's platform utilizes network science to unite complex, multi-dimensional data and extract signals and networks of relationships, which would otherwise be undetectable by humans alone. Its approach addresses the opportunities and challenges in the burgeoning field of the microbiome, which is at the frontier of science today.
In September 27, 2023, Eagle Genomics successfully secured a £3.00M Venture Round investment from Abrdn, ETF Partners, and Granpool Innovative Investments, demonstrating the confidence of notable investors in the company's vision and potential impact. With its innovative approach and significant recent investment, Eagle Genomics is poised to continue its groundbreaking work in microbiome science.
